A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may
control evasion of the immune response in tumors. The goal of this clinical trial is to learn
whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2
including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. The main
questions it aims to answer are:
- what is an appropriate dose to be given to patients?
- are the side effects of treatment manageable?
Participants will be evaluated for participation in the study. Patients who are treated will
receive an intravenous infusion of NPX267 every three weeks if their disease has not
progressed. Patients will be closely monitored by the treating physician.